BlueWind Medical Secures $47.8M for Revi Implantable Tibial Neuromodulation System
Summary
BlueWind Medical has closed $47.8 million in equity and debt financing to accelerate commercialization of the Revi System, an implantable tibial neuromodulation device for urgency urinary incontinence. Revi is implanted near the ankle in a single outpatient procedure under local anesthesia and delivers targeted stimulation to the posterior tibial nerve via a lightweight external wearable. The financing follows three-year results from the pivotal OASIS study confirming sustained efficacy, excellent safety, and 95% patient satisfaction at 36 months.
Why it matters
This financing demonstrates investor confidence in expanding neuromodulation beyond traditional brain and spinal cord applications into peripheral nerve targets for large patient populations. With over 300 million people worldwide affected by urgency urinary incontinence, many of whom cannot tolerate or do not respond to medications, Revi offers a drug-free alternative that avoids the complications of battery-powered implants. The strong clinical data package and high patient satisfaction rates position BlueWind to establish a new standard of care.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial